We then assessed the specific associations of the different Aβ and tau biomarkers with distinct aspects of AD neuropathology, including established neuropathologic rating scales for regional extension of Aβ pathology (Thal phases), cortical density of diffuse and neuritic Aβ plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD] score), and regional extension of neurofibrillary tangle tau pathology (Braak stages). The gene discussed is MAPT; the disease is Alzheimer disease.